SBC Medical Group Holdings Inc. (NASDAQ: SBC), a Japanese operator of aesthetic medical clinics and provider of consulting services, has completed a strategic investment in OrangeTwist, a U.S.-based medspa chain. The move signals the company's official entry into the U.S. market and its ambition to become a global leader in the medical aesthetics industry.
OrangeTwist specializes in non-invasive aesthetic treatments and operates 24 locations across six U.S. states. The partnership will involve joint operations, leveraging synergies in the U.S. and Asia. OrangeTwist's advanced management system, which integrates procurement, clinical workflows, and real-time KPI tracking, aligns with SBC's operational expertise. Healthcare-focused private equity firm Hildred Capital and Athyrium Capital are also longstanding institutional shareholders in OrangeTwist.
The U.S. medical aesthetics industry is forecast to grow from $34 billion to $48 billion by 2030, driven by demand for non-surgical treatments such as injectables, fillers, laser treatments, and body contouring. SBC aims to provide funding and professional know-how to help OrangeTwist enhance its offerings and address 'white space' in markets with high demand but few competitors. 'As part of SBC's global expansion, we are working hard to find local partnerships rather than copying and pasting what we did in Japan,' Stephen Rodgers, global head of planning and strategy at SBC Medical, told Benzinga in an interview.
Beyond the U.S., SBC is also expanding in Japan and Southeast Asia. The company's growth strategy rests on three core tenets: partnering with high-performing regional operators with scalable business models, deploying SBC's expertise to drive efficiencies, and securing first-mover advantages. In Asia, non-invasive cosmetic treatments are in demand because customers prefer natural-looking results with minimal recovery times. By standardizing services, SBC ensures consistent quality across its clinics.
SBC is also positioning itself to capitalize on the growing longevity industry, which is shifting from increasing lifespan to boosting 'healthspan' through personalized, preventative, and tech-driven solutions. According to Gabelli Research, the global anti-aging market, valued at approximately $85 billion in 2025, is expected to surpass $120 billion by 2030. North America accounts for about 30% of the market, while robust growth also comes from Asia.
With its partnership model, SBC Medical aims to build a global network by sharing its successful approach with local providers. To learn more about SBC Medical, click here.
This content was originally published on Benzinga. Read further disclosures here.
